Translations:GLP-1 receptor agonist/20/ja: Difference between revisions

From Azupedia
Jump to navigation Jump to search
VisualWikitext
Created page with "==承認済み== {{Anchor|Approved}} *エクセナチド（商品名バイエッタ(Byetta)、ビデュリオン(Bydureon)、アストラゼネカ社製）、2005年/2012年承認。 *リラグルチド（糖尿病治療薬ビクトーザ(Victoza)、肥満治療薬サクセンダ(Saxenda)、ノボ・ノルディスク社製）、2010年承認 *アルビグルチド（タンゼウム(T..."
 
(No difference)

Latest revision as of 16:57, 6 February 2024

Information about message (contribute)
This message has no documentation. If you know where or how this message is used, you can help other translators by adding documentation to this message.
Message definition (GLP-1 receptor agonist)
==Approved==
*[[exenatide]] (brand names Byetta and Bydureon, manufactured by [[AstraZeneca]]), approved in 2005/2012
*[[liraglutide]] (Victoza for diabetes, Saxenda for obesity, manufactured by [[Novo Nordisk]]), approved in 2010
*[[albiglutide]] (Tanzeum, manufactured by [[GlaxoSmithKline|GSK]]), approved in 2014
*[[dulaglutide]] (Trulicity, manufactured by [[Eli Lilly and Company|Eli Lilly]]), approved in 2014
*[[lixisenatide]] (Lyxumia in Europe, Adlyxin in the United States, manufactured by [[Sanofi]]), approved in 2016
*[[semaglutide]] (Ozempic and Rybelsus for diabetes, Wegovy for obesity, manufactured by Novo Nordisk), approved in 2017
*[[tirzepatide]] (dual GLP-1 and [[Gastric inhibitory polypeptide receptor|GIP]] agonist; Mounjaro for diabetes, Zepbound for obesity, manufactured by Eli Lilly), approved in 2022

承認済み

Retrieved from "https://wiki.tiffa.net/w/index.php?title=Translations:GLP-1_receptor_agonist/20/ja&oldid=111588"